AU2018307983B2 - Methods of treating myelodysplastic syndrome - Google Patents

Methods of treating myelodysplastic syndrome Download PDF

Info

Publication number
AU2018307983B2
AU2018307983B2 AU2018307983A AU2018307983A AU2018307983B2 AU 2018307983 B2 AU2018307983 B2 AU 2018307983B2 AU 2018307983 A AU2018307983 A AU 2018307983A AU 2018307983 A AU2018307983 A AU 2018307983A AU 2018307983 B2 AU2018307983 B2 AU 2018307983B2
Authority
AU
Australia
Prior art keywords
subject
mds
imetelstat
weeks
telomerase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018307983A
Other languages
English (en)
Other versions
AU2018307983A1 (en
Inventor
Jacqueline Cirillo BUSSOLARI
Aleksandra RIZO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018307983(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU2018307983A1 publication Critical patent/AU2018307983A1/en
Application granted granted Critical
Publication of AU2018307983B2 publication Critical patent/AU2018307983B2/en
Priority to AU2024219941A priority Critical patent/AU2024219941A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018307983A 2017-07-28 2018-07-27 Methods of treating myelodysplastic syndrome Active AU2018307983B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024219941A AU2024219941A1 (en) 2017-07-28 2024-09-20 Methods of treating myelodysplastic syndrome

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US62/538,315 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US62/595,329 2017-12-06
US201862685542P 2018-06-15 2018-06-15
US62/685,542 2018-06-15
PCT/US2018/044225 WO2019023667A1 (en) 2017-07-28 2018-07-27 METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219941A Division AU2024219941A1 (en) 2017-07-28 2024-09-20 Methods of treating myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
AU2018307983A1 AU2018307983A1 (en) 2020-02-13
AU2018307983B2 true AU2018307983B2 (en) 2024-07-18

Family

ID=63209674

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018307983A Active AU2018307983B2 (en) 2017-07-28 2018-07-27 Methods of treating myelodysplastic syndrome
AU2024219941A Pending AU2024219941A1 (en) 2017-07-28 2024-09-20 Methods of treating myelodysplastic syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219941A Pending AU2024219941A1 (en) 2017-07-28 2024-09-20 Methods of treating myelodysplastic syndrome

Country Status (17)

Country Link
US (1) US12171778B2 (enExample)
EP (1) EP3658156A1 (enExample)
JP (4) JP7316261B2 (enExample)
KR (2) KR102867725B1 (enExample)
CN (1) CN110944646A (enExample)
AU (2) AU2018307983B2 (enExample)
BR (1) BR112020001749A2 (enExample)
CA (1) CA3069010A1 (enExample)
CL (2) CL2020000196A1 (enExample)
IL (1) IL272163B1 (enExample)
MA (1) MA49688A (enExample)
MX (1) MX2025005894A (enExample)
SG (1) SG11201913984RA (enExample)
TW (1) TWI879717B (enExample)
UA (1) UA127701C2 (enExample)
WO (1) WO2019023667A1 (enExample)
ZA (1) ZA202000070B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法
SG11202105573PA (en) 2018-11-29 2021-06-29 Geron Corp Methods of treating myelodysplastic syndrome
CN115776909A (zh) 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
WO2001053307A1 (en) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
WO2002077184A2 (en) 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
AU2004289975B2 (en) 2003-11-04 2011-11-03 Geron Corporation RNA amidates and thioamidates for RNAI
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
EP1910342A1 (en) 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
PL2101789T3 (pl) 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9155753B2 (en) 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
PT3029154T (pt) 2008-10-17 2017-12-06 Geron Corp Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase
US8772264B2 (en) 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
EP2534261B1 (en) 2010-02-12 2016-11-30 QIAGEN Marseille Asxl1 as a new diagnostic marker of myeloid neoplasms
US8460872B2 (en) 2011-04-29 2013-06-11 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
ES2972330T3 (es) 2012-11-30 2024-06-12 Geron Corp Marcadores diagnósticos para el tratamiento de trastornos proliferativos celulares con inhibidores de la telomerasa
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
ES2717777T3 (es) * 2013-11-06 2019-06-25 Mayo Found Medical Education & Res Métodos y materiales para tratar neoplasias hematológicas
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法

Also Published As

Publication number Publication date
KR20200033269A (ko) 2020-03-27
TWI879717B (zh) 2025-04-11
NZ760873A (en) 2024-03-22
KR102867725B1 (ko) 2025-10-13
EP3658156A1 (en) 2020-06-03
CL2021001096A1 (es) 2021-11-12
JP7654761B2 (ja) 2025-04-01
TW201919705A (zh) 2019-06-01
JP7654615B2 (ja) 2025-04-01
JP2024015000A (ja) 2024-02-01
US20190030064A1 (en) 2019-01-31
JP2020528915A (ja) 2020-10-01
JP7316261B2 (ja) 2023-07-27
JP2025013669A (ja) 2025-01-24
IL272163A (en) 2020-03-31
CL2020000196A1 (es) 2020-11-20
UA127701C2 (uk) 2023-12-06
CA3069010A1 (en) 2019-01-31
JP2023009229A (ja) 2023-01-19
AU2018307983A1 (en) 2020-02-13
MA49688A (fr) 2020-06-03
AU2024219941A1 (en) 2024-10-10
TW202432146A (zh) 2024-08-16
CN110944646A (zh) 2020-03-31
KR20250151565A (ko) 2025-10-21
MX2025005894A (es) 2025-06-02
IL272163B1 (en) 2025-12-01
WO2019023667A1 (en) 2019-01-31
US12171778B2 (en) 2024-12-24
SG11201913984RA (en) 2020-02-27
ZA202000070B (en) 2025-09-25
BR112020001749A2 (pt) 2020-07-21

Similar Documents

Publication Publication Date Title
JP7654761B2 (ja) 骨髄異形成症候群の治療方法
KR102854375B1 (ko) 혈액 암을 위한 조합 치료법
US20250170160A1 (en) Methods of Treating Myelodysplastic Syndrome
TWI906757B (zh) 治療骨髓增生不良症候群之方法
EA050072B1 (ru) Способы лечения миелодиспластического синдрома
HK40027129A (en) Methods of treating myelodysplastic syndrome
EA043524B1 (ru) Способы лечения миелодиспластического синдрома
HK40063245A (en) Methods of treating myelodysplastic syndrome
EA045910B1 (ru) Способы лечения миелодиспластического синдрома
BR112019002025B1 (pt) Usos de uma combinação de imetelstat e abt-199 ou um sal farmaceuticamente aceitável do mesmo, kit, método in vitro para induzir apoptose e composição farmacêutica
BR122024018240A2 (pt) Uso de inibidores de telomerase e de bcl-2 e suas combinações, uso de imetelstat e abt-199 ou sais dos mesmos e suas combinações, kit, método in vitro para induzir apoptose, e composição farmacêutica

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)